vs
Side-by-side financial comparison of Arbutus Biopharma Corp (ABUS) and Satellogic Inc. (SATL). Click either name above to swap in a different company.
Arbutus Biopharma Corp is the larger business by last-quarter revenue ($10.7M vs $6.2M, roughly 1.7× Satellogic Inc.). Satellogic Inc. runs the higher net margin — 488.0% vs 23.5%, a 464.5% gap on every dollar of revenue.
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
Satellogic Inc. is an American company specializing in Earth-observation satellites, founded in 2010 by Emiliano Kargieman and Gerardo Richarte.
ABUS vs SATL — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $10.7M | $6.2M |
| Net Profit | $2.5M | $30.5M |
| Gross Margin | — | — |
| Operating Margin | 13.9% | -114.2% |
| Net Margin | 23.5% | 488.0% |
| Revenue YoY | 522.2% | — |
| Net Profit YoY | 112.7% | — |
| EPS (diluted) | $0.01 | $0.24 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $6.2M | ||
| Q3 25 | — | $3.6M | ||
| Q2 25 | $10.7M | $4.4M | ||
| Q1 25 | — | $3.4M | ||
| Q2 24 | — | $3.5M | ||
| Q4 23 | $2.1M | — | ||
| Q3 23 | $4.7M | — | ||
| Q2 23 | $4.7M | — |
| Q4 25 | — | $30.5M | ||
| Q3 25 | — | $4.0M | ||
| Q2 25 | $2.5M | $-6.7M | ||
| Q1 25 | — | $-32.6M | ||
| Q2 24 | — | $-18.1M | ||
| Q4 23 | — | — | ||
| Q3 23 | $-20.1M | — | ||
| Q2 23 | $-17.1M | — |
| Q4 25 | — | -114.2% | ||
| Q3 25 | — | -222.5% | ||
| Q2 25 | 13.9% | -141.6% | ||
| Q1 25 | — | -280.9% | ||
| Q2 24 | — | -419.2% | ||
| Q4 23 | -967.2% | — | ||
| Q3 23 | -462.8% | — | ||
| Q2 23 | -395.3% | — |
| Q4 25 | — | 488.0% | ||
| Q3 25 | — | 109.2% | ||
| Q2 25 | 23.5% | -149.8% | ||
| Q1 25 | — | -961.9% | ||
| Q2 24 | — | -517.0% | ||
| Q4 23 | — | — | ||
| Q3 23 | -431.6% | — | ||
| Q2 23 | -367.5% | — |
| Q4 25 | — | $0.24 | ||
| Q3 25 | — | $-0.02 | ||
| Q2 25 | $0.01 | $-0.06 | ||
| Q1 25 | — | $-0.34 | ||
| Q2 24 | — | $-0.20 | ||
| Q4 23 | $-0.12 | — | ||
| Q3 23 | $-0.12 | — | ||
| Q2 23 | $-0.10 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $37.4M | $94.4M |
| Total DebtLower is stronger | $0 | — |
| Stockholders' EquityBook value | $83.0M | $60.5M |
| Total Assets | $103.3M | $151.3M |
| Debt / EquityLower = less leverage | 0.00× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $94.4M | ||
| Q3 25 | — | $28.3M | ||
| Q2 25 | $37.4M | $32.6M | ||
| Q1 25 | — | $17.7M | ||
| Q2 24 | — | $25.6M | ||
| Q4 23 | $126.0M | — | ||
| Q3 23 | $17.5M | — | ||
| Q2 23 | $27.2M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $0 | — | ||
| Q1 25 | — | — | ||
| Q2 24 | — | — | ||
| Q4 23 | $0 | — | ||
| Q3 23 | $0 | — | ||
| Q2 23 | $0 | — |
| Q4 25 | — | $60.5M | ||
| Q3 25 | — | $-56.9M | ||
| Q2 25 | $83.0M | $-68.1M | ||
| Q1 25 | — | $-83.1M | ||
| Q2 24 | — | $19.1M | ||
| Q4 23 | $106.0M | — | ||
| Q3 23 | $119.3M | — | ||
| Q2 23 | $134.7M | — |
| Q4 25 | — | $151.3M | ||
| Q3 25 | — | $70.9M | ||
| Q2 25 | $103.3M | $73.8M | ||
| Q1 25 | — | $61.4M | ||
| Q2 24 | — | $76.6M | ||
| Q4 23 | $144.4M | — | ||
| Q3 23 | $158.6M | — | ||
| Q2 23 | $176.8M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.00× | — | ||
| Q1 25 | — | — | ||
| Q2 24 | — | — | ||
| Q4 23 | 0.00× | — | ||
| Q3 23 | 0.00× | — | ||
| Q2 23 | 0.00× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.7M | $-9.5M |
| Free Cash FlowOCF − Capex | — | $-12.8M |
| FCF MarginFCF / Revenue | — | -204.9% |
| Capex IntensityCapex / Revenue | 0.0% | 53.6% |
| Cash ConversionOCF / Net Profit | -6.24× | -0.31× |
| TTM Free Cash FlowTrailing 4 quarters | — | $-34.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-9.5M | ||
| Q3 25 | — | $-8.4M | ||
| Q2 25 | $-15.7M | $-4.3M | ||
| Q1 25 | — | $-4.7M | ||
| Q2 24 | — | — | ||
| Q4 23 | $-17.3M | — | ||
| Q3 23 | $-21.8M | — | ||
| Q2 23 | $-19.6M | — |
| Q4 25 | — | $-12.8M | ||
| Q3 25 | — | $-9.7M | ||
| Q2 25 | — | $-5.1M | ||
| Q1 25 | — | $-6.6M | ||
| Q2 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | $-21.8M | — | ||
| Q2 23 | $-20.4M | — |
| Q4 25 | — | -204.9% | ||
| Q3 25 | — | -267.2% | ||
| Q2 25 | — | -115.3% | ||
| Q1 25 | — | -195.9% | ||
| Q2 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | -468.4% | — | ||
| Q2 23 | -439.0% | — |
| Q4 25 | — | 53.6% | ||
| Q3 25 | — | 36.8% | ||
| Q2 25 | 0.0% | 17.5% | ||
| Q1 25 | — | 56.5% | ||
| Q2 24 | — | — | ||
| Q4 23 | 0.0% | — | ||
| Q3 23 | 0.7% | — | ||
| Q2 23 | 18.5% | — |
| Q4 25 | — | -0.31× | ||
| Q3 25 | — | -2.11× | ||
| Q2 25 | -6.24× | — | ||
| Q1 25 | — | — | ||
| Q2 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ABUS
Segment breakdown not available.
SATL
| Transferred At Point In Time | $5.7M | 91% |
| Other | $547.0K | 9% |
